Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521176 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL29420217 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL12342733 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL521869 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL3280673 | 0.99 | CACNA2D1 (0.74) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL3358201 | 0.99 | CACNA2D1 (0.74) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL1535363 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL3312526 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Phosphoric Acid SCHEMBL1535335 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL2740 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163415-B | Preparation method of duloxetine hydrochloride intermediate | 珠海润都制药股份有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-114163415-A | Preparation method of duloxetine hydrochloride intermediate | 珠海润都制药股份有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-107382958-A | A kind of method for crystallising of duloxetine. intermediate | 浙江华海药业股份有限公司 | 2017-11-24 | — | — | CN | claimed |
| CN-103896910-B | A kind of synthetic method of duloxetine | CHENGDU GUOHONG MEDICINE CO., LTD. (CN) | 2016-02-03 | — | — | CN | claimed |
| EP-2172464-B1 | A method for the preparation of the hydrochloride salt from the duloxetine base | ZENTIVA KS (CZ) | 2015-08-26 | — | — | EP | claimed |
| CN-104163811-A | New method for preparation of duloxetine hydrochloride | CHONGQING SHENGHUAXI PHARMA CO | 2014-11-26 | — | — | CN | claimed |
| CN-103896910-A | Synthetic method of duloxetine | CHENGDU GUOHONG PHARMACEUTICAL CO LTD | 2014-07-02 | — | — | CN | claimed |
| EP-2132192-B1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LTD (IN) | 2013-04-24 | — | — | EP | claimed |
| EP-2508519-A1 | \"Process for the preparation of duloxetine and its hydrochloride salt\ | Bioindustria Laboratorio Italiano Medicinali S.p.A In forma abbreviata Bioindustria L.I.M. S.p.A. (IT) | 2012-10-10 | — | — | EP | claimed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | claimed |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | SUN PHAMACEUUTICAL INDUSTRIES LTD. (IN) | 2007-08-16 | — | — | US | claimed |
| US-20070167636-A1 | IMPROVED PROCESS FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE | ELI LILLY AND COMPANY | 2007-07-19 | — | — | US | claimed |
| CN-1300137-C | Method for preparing (S)-(+)-N,N-dimethyl-3-(1-naphthoxy)-3-(2-thienyl) propylamine | SHANGHAI PHARMACEUTICAL INDUST (CN) | 2007-02-14 | — | — | CN | claimed |
| WO-2006027798-A2 | A PROCESS FOR PREPARATION OF AN ANTIDEPRESSANT COMPOUND | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| CN-1676522-A | Method for preparing (S)-(+)-N,N-dimethyl-3-(1-naphthoxy)-3-(2-thienyl) propylamine | SHANGHAI PHARMACEUTICAL INDUST (CN) | 2005-10-05 | — | — | CN | claimed |
| EP-0650965-B1 | Asymmetric synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine an intermediate in the preparation of duloxetine | LILLY CO ELI (US) | 2001-02-07 | — | — | EP | claimed |
| US-5491243-A | Intermediate useful for the asymmetric synthesis of duloxetine | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| EP-0650965-A1 | Asymmetric synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine an intermediate in the preparation of duloxetine | ELI LILLY AND COMPANY (US) | 1995-05-03 | — | — | EP | claimed |
| US-5362886-A | Asymmetric synthesis | ELI LILLY AND COMPANY (US) | 1994-11-08 | — | — | US | claimed |
| EP-0457559-A2 | Chiral synthesis of 1-aryl-3-aminopropan-1-ols | ELI LILLY AND COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167636-A1 | IMPROVED PROCESS FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE | CYP2D6, TPH2, TPH1 | CACNA2D1 2161/4885SLC6A2 44/4885SLC6A4 33/4885 |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | TPH1, TPH2, HTR4 | CACNA2D1 908/4885SLC6A2 13/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.